Figure S3 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma | Synapse
August 4, 2025
Figure S3 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma
Key Points
MAIN FINDING: Multi-selective inhibitor therapy promotes long-term control of tumors in pancreatic ductal adenocarcinoma.
KEY EVIDENCE: Inhibition is linked to senescence-associated mechanisms and impacts immune equilibrium in tumors.
APPROACH: The study identifies tumor cell subsets and their senescence gene signatures following therapy.
SIGNIFICANCE: Findings provide insights into new therapeutic strategies that leverage tumor-immune interactions in cancer treatment.
Abstract
Identification of tumor cell subsets expressing senescence gene signatures